Low bone mass in Pompe disease. Muscular strength as a predictor of bone mineral density

Bone

Volumn 47, Issue 3, 2010, Pages 643-649

  van den Berg, Linda E M ^a   Zandbergen, Adrienne A ^a   van Capelle, Carine I ^a   de Vries, Juna M ^a   Hop, Wim C ^a   van den Hout, Johanna M ^a   Reuser, Arnold J J ^a   Zillikens, M Carola ^a   van der Ploeg, Ans T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bone densitometry; Metabolic muscle disease; Muscle strength; Osteoporosis; Pompe disease

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CHILD; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LUMBAR SPINE; MALE; MUSCLE STRENGTH; OSTEOPOROSIS; PREDICTION; PRESCHOOL CHILD; PROGNOSIS; SCHOOL CHILD;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; ALPHA-GLUCOSIDASES; BONE DENSITY; CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MUSCLE STRENGTH;

EID: 77955842384     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.06.021     Document Type: Article

References (37)

1. Hirschorn R., Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. The metabolic and molecular bases of inherited disease 2001, 3389-3420. Mc Graw-Hill. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, M.D. Valle (Eds.).
2. van der Ploeg A.T., Reuser A.J. Pompe's disease. Lancet Oct 11 2008, 372(9646):1342-1353.
3. van den Hout H.M., Hop W., van Diggelen O.P., Smeitink J.A., Smit G.P., Poll-The B.T., et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics Aug 2003, 112(2):332-340.
4. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D., et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr May 2006, 148(5):671-676.
5. Winkel L.P., Hagemans M.L., van Doorn P.A., Loonen M.C., Hop W.J., Reuser A.J., et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol Aug 2005, 252(8):875-884.
6. Wokke J.H., Escolar D.M., Pestronk A., Jaffe K.M., Carter G.T., van den Berg L.H., et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve Oct 2008, 38(4):1236-1245.
7. Montalvo A.L., Bembi B., Donnarumma M., Filocamo M., Parenti G., Rossi M., et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat Oct 2006, 27(10):999-1006.
8. Kroos M.A., Pomponio R.J., Hagemans M.L., Keulemans J.L., Phipps M., DeRiso M., et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology Jan 9 2007, 68(2):110-115.
9. Van den Hout J.M., Kamphoven J.H., Winkel L.P., Arts W.F., De Klerk J.B., Loonen M.C., et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics May 2004, 113(5):e448-e457.
10. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology Jan 9 2007, 68(2):99-109.
11. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der Ploeg A., Clancy J.P., et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res Sep 2009, 66(3):329-335.
12. van Capelle C.I., Winkel L.P., Hagemans M.L., Shapira S.K., Arts W.F., van Doorn P.A., et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord Jun 2008, 18(6):447-452.
13. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol Jan 2010, 257(1):91-97.
14. Formica C.A., Cosman F., Nieves J., Herbert J., Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int Aug 1997, 61(2):129-133.
15. Khatri I.A., Chaudhry U.S., Seikaly M.G., Browne R.H., Iannaccone S.T. Low bone mineral density in spinal muscular atrophy. J Clin Neuromuscul Dis Sep 2008, 10(1):11-17.
16. Soderpalm A.C., Magnusson P., Ahlander A.C., Karlsson J., Kroksmark A.K., Tulinius M., et al. Bone markers and bone mineral density in Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact 2008, 8(1):24.
17. Pastores G.M., Meere P.A. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005, 17(1):70-78.
18. Mersebach H., Johansson J.O., Rasmussen A.K., Bengtsson B.A., Rosenberg K., Hasholt L., et al. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 2007, 9(12):812-818.
19. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285(6):785-795.
20. Case L.E., Hanna R., Frush D.P., Krishnamurthy V., DeArmey S., Mackey J., et al. Fractures in children with Pompe disease: a potential long-term complication. Pediatr Radiol 2007, 37(5):437-445.
21. van der Sluis I.M., de Ridder M.A., Boot A.M., Krenning E.P., de Muinck Keizer-Schrama S.M. Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child 2002, 87(4):341-347. [discussion 341-7].
22. Baim S., Binkley N., Bilezikian J.P., Kendler D.L., Hans D.B., Lewiecki E.M., et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008, 11(1):75-91.
23. Beenakker E.A., van der Hoeven J.H., Fock J.M., Maurits N.M. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16years by hand-held dynamometry. Neuromuscul Disord 2001, 11(5):441-446.
24. Seeman E., Hopper J.L., Bach L.A., Cooper M.E., Parkinson E., McKay J., et al. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med 1989, 320(9):554-558.
25. Kelsey J.L. Risk factors for osteoporosis and associated fractures. Public Health Rep 1989, 104 Suppl:14-20.
26. Sabo D., Blaich S., Wenz W., Hohmann M., Loew M., Gerner H.J. Osteoporosis in patients with paralysis after spinal cord injury. A cross sectional study in 46 male patients with dual-energy X-ray absorptiometry. Arch Orthop Trauma Surg 2001, 121(1-2):75-78.
27. Taaffe D.R., Cauley J.A., Danielson M., Nevitt M.C., Lang T.F., Bauer D.C., et al. Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: the Health, Aging, and Body Composition Study. J Bone Miner Res 2001, 16(7):1343-1352.
28. Bechtold S., Ripperger P., Dalla Pozza R., Schmidt H., Hafner R., Schwarz H.P. Musculoskeletal and functional muscle-bone analysis in children with rheumatic disease using peripheral quantitative computed tomography. Osteoporos Int 2005, 16(7):757-763.
29. Frost H.M. Bone "mass" and the "mechanostat": a proposal. Anat Rec 1987, 219(1):1-9.
30. Snow-Harter C., Bouxsein M., Lewis B., Charette S., Weinstein P., Marcus R. Muscle strength as a predictor of bone mineral density in young women. J Bone Miner Res 1990, 5(6):589-595.
31. Kontulainen S.A., Hughes J.M., Macdonald H.M., Johnston J.D. The biomechanical basis of bone strength development during growth. Med Sport Sci 2007, 51:13-32.
32. Crabtree N.J., Kibirige M.S., Fordham J.N., Banks L.M., Muntoni F., Chinn D., et al. The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004, 35(4):965-972.
33. Bianchi M.L. Osteoporosis in children and adolescents. Bone 2007, 41(4):486-495.
34. Slonim A.E., Bulone L., Goldberg T., Minikes J., Slonim E., Galanko J., et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007, 35(1):70-77.
35. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339(14):947-952.
36. Bianchi M.L., Cimaz R., Bardare M., Zulian F., Lepore L., Boncompagni A., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000, 43(9):1960-1966.
37. Shaw N.J., Bishop N.J. Bisphosphonate treatment of bone disease. Arch Dis Child 2005, 90(5):494-499.